Nov 15 (Reuters) - Roche Holding AG:
* CHMP RECOMMENDS EU APPROVAL OF ROCHE’S KADCYLA FOR THE ADJUVANT TREATMENT OF PEOPLE WITH HER2-POSITIVE EARLY BREAST CANCER WITH RESIDUAL INVASIVE DISEASE AFTER NEOADJUVANT TREATMENT Source text for Eikon: Further company coverage: (Reporting by Berlin Speed Desk)